Skip to main content

A Mathematical Model for Growing Metastases on Oncologists’s Service

  • Chapter
  • First Online:
  • 821 Accesses

Abstract

The dual classification of cancer as localized or metastatic disease is one of the key points in the elaboration of the best therapy for each patient. Nevertheless, many studies reveal that part of these localized diseases is already metastatic. The presence of undetectable or micro-metastases explains the necessity of adjuvant chemotherapies after resection of the primary tumor even for some T1N0M0 cancer. There is probably a continuum between these two stages.We expose here how a mathematical model of growing metastases could reflect this continuum of the disease and how such a model could help the oncologists in the choice of the treatment. This phenomenological model is based on a structured transport equations with nonlocal boundary condition describing the evolution of the density of metastasis. Thanks to this model, we forge a new numerical index, that we call Metastatic Index, able to reveal either the micro-metastatic state of the patient, or the visible metastatic one. Numerical illustrations show how this new index can be used.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Barbolosi D, Benabdallah A, Hubert F, Verga F (2009) Mathematical and numerical analysis for a model of growing metastatic tumors. Math Biosci 218:1–14

    Article  MathSciNet  MATH  Google Scholar 

  2. Benzekry S (2011) Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis. J Evol Equat 11(1):187–213

    Article  MATH  Google Scholar 

  3. Benzekry S (2011) Mathematical and numerical analysis of the anti-angiogenic therapy in metastatic cancers. Esaim Math Model Numer Anal 46(2):207–237

    Article  MathSciNet  Google Scholar 

  4. Elias D (2006) Rationnel de la chirurgie oncologique au sein du traitement multimodal des cancers. Bull Cancer 93:775–781

    Google Scholar 

  5. Hahnfeldt P, Panigraphy D, Folkman J, Hlatky L (1999) Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment, response and postvascular dormancy. Cancer Res 59:4770–4775

    Google Scholar 

  6. Iwata K, Kawasaki K, Shigesada N (2000) A dynamical model for the growth and size distribution of multiple metastatic tumors. J Theor Biol 203:177–186

    Article  Google Scholar 

  7. Koscielny S, Tubiana M, Le MG et al (1984) Breast cancer. Relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49:709–715

    Article  Google Scholar 

  8. Meille C (2009) Modélisation du risque des toxicités induites par des substances thérapeutiques. Ph.D. thesis, Université de la Méditerranée, France, 21 March

    Google Scholar 

  9. Meille C, Iliadis A, Barbolosi D et al (2008) An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokin Pharmacodyn 35:619–633

    Article  Google Scholar 

  10. Peeters C, phal JR, de Geus LF, Wetphal JR et al (2005) Decrease in circulating anti-angiogenic factors after removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 137:246–249

    Google Scholar 

  11. Verga F (2010) Modélisation mathématique du processus métastatique. Ph.D. thesis, Université de Provence, France, 23 November

    Google Scholar 

  12. Verga F, You B, Benabdallah A, Hubert F, Faivre C, Mercier C, Ciccolini J, Barbolosi D (2011) Modélisation du risque d’évolution métastatique chez les patients supposés avoir une maladie localisée. Oncologie 13(8):528–533

    Article  Google Scholar 

  13. Viens P, Roché H, Kerbrat P et al (2001) Epirubicin-docetaxel combination in first line chemotherapy for patients with metastatic breast cancer. J Clin Oncol 24:328–335

    Article  Google Scholar 

  14. You B (2009) Inhibiteurs de tyrosine kinase et chimiothrapie: et si ctait seulement une question de scheduling? France Cancer, 19 janvier, 440

    Google Scholar 

  15. You B, Meille C, Barbolosi D, Tranchand B, Guitton J, Rioufol C, Iliadis A, Freyer G (2007). A mechanistic model predicting hematopoiesis and tumor growth to optimize docetaxel + epirubicin (ET) administration in metastatic breast cancer (MBC): phase I trial. J Clin Oncol 25:13013

    Google Scholar 

Download references

Acknowledgments

The authors were partially supported by l’Agence Nationale de la recherche under Grant ANR JC07-07-JCJC-0139-01.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F. Hubert .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer New York

About this chapter

Cite this chapter

Barbolosi, D. et al. (2014). A Mathematical Model for Growing Metastases on Oncologists’s Service. In: Garbey, M., Bass, B., Berceli, S., Collet, C., Cerveri, P. (eds) Computational Surgery and Dual Training. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8648-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8648-0_21

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8647-3

  • Online ISBN: 978-1-4614-8648-0

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics